Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231309 · ClinicalTrials.gov registry record · NA
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
A NA study of Hematologic Malignancies and Hematologic Diseases, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00231309: Completed NA study of Hematologic Malignancies and Hematologic Diseases, sponsored by Emory University.
NCT00231309 is a NA study of Hematologic Malignancies and Hematologic Diseases that has completed, run by Emory University. The registered enrollment target is 10 participants, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00231309, a NA study of Hematologic Malignancies and Hematologic Diseases, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to participate in the study. Donors will receive the white cell growth hormone (G-CSF) as a shot (injection) in their arm once a day for three days before they donate their bone marrow cells. Total body irradiation and/or chemotherapy will be given first to prepare the patient's body for the infusion of new bone marrow cells from the donor. Two medicines (cyclosporine and methotrexate) will be used to prevent the new bone marrow cells (graft) from attacking the patient's body (host) (graft-versus-host disease; GVHD). Certain safety checkpoints were built into the study if unwanted/unexpected events were to occur. If the outcomes appear better than could be expected, this will provide a bridge to extend this current approach for other innovative therapies.
Primary Outcome
Evaluate the numbers of participants with disease-free survival
Conditions Studied
Interventions
- DRUG Granulocyte Colony Stimulating Factor
Study Locations (1)
Georgia
- Children's Healthcare of Atlanta/Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT00231309 record still lists
NCT00231309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Granulocyte Colony Stimulating Factor is the first listed.
NCT00231309 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00231309 about?
NCT00231309 is a clinical study titled "Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)". The major purpose of this study is to evaluate the curative potential of white cell growth hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients with cancers or blood diseases, who have poor potential for a cure with standard treatment, will be able to particip...
What is the current status of trial NCT00231309?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2003-07. Estimated completion is 2011-11.
What conditions does trial NCT00231309 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Hematologic Diseases.
What interventions are being tested in trial NCT00231309?
The interventions under investigation include: Granulocyte Colony Stimulating Factor (DRUG).
Who is sponsoring clinical trial NCT00231309?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00231309 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00231309's enrollment target sits among peer trials
10 46th of 45 the lowest of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
RECRUITING · NA
-
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
RECRUITING · NA
-
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
COMPLETED · NA
-
IUdR/BUdR Cell Cycle Labelling
COMPLETED · NA
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia